Ninety percent of human diseases are related to abnormal inflammation. WJM team has successfully developed a new monoclonal antibody that can inhibit a key inflammation protein. Animal experiments have accumulated more than ten disease modes, including a variety of solid tumors, fibrosis, degenerativecardiovascular diseases. This antibody is qualified as an orphan drug for the treatment of IPF. New coronary pneumonia has greatly increased the demand for pulmonary fibrosis treatment,has also become an important target for mergersacquisitions of global pharmaceutical companies.

Our system is achieved by integrating diffractiondeep learning methods, which allows high-throughput lensless imaging system to display wide rangehigh-resolution images. In addition, the developed extraction chipsprototype were verified to accurately detect the numberproportion of blood cells under low blood demand. Our system shows great potential in point-of-care blood cells monitoring for cancer patients that could reduce infection riskmortality rate, increase efficacy of chemotherapysupport precision medicine.

We have synthesized the LiYF4:Ce3+ nanoparticles – Methotrexate (MTX), targeting pancreatic cancer cells via folate receptors. Under ultralow 0.1 Gy X-ray irradiation (the lowest dose in the world, for 2-3 times), the nanoparticles can exhibit radiosensitization effect,radiosensitizing chemotherapy, because of MTX released by X-ray inducing photocleavage of NPA linker. The dual sensitization effect will enhance ROS production, DNA damage, cell cycle S phase arrest in pancreatic cancer cells. We have also demonstrated the excellent efficacy in AsPC-1PANC-1 xenografted pancreatic mice.